secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001641172-25-009996
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra Q1 net loss $3.1M, cash $3.2M; secures up to $20M funding from Alumni Capital
--------------------------------------------------------------------------------

- Net loss $3.1M for Q1 2025 vs $2.9M in Q1 2024; R&D $1.3M, G&A $1.9M.
- Cash $3.2M as of March 31, 2025; signed up to $20M purchase agreement with Alumni Capital LP.
- Closed two public offerings raising $2.2M.
- ATR-12 Phase 1b initial safety data expected 1H 2025; topline data by YE 2025.
- ATR-04 Phase 1/2 first patient dosing expected 1H 2025; ASCO poster accepted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000164117225009996/0001641172-25-009996-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000164117225009996/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-009996

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer